| 000 | 01619 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515150106.0 | ||
| 264 | 0 | _c20090217 | |
| 008 | 200902s 0 0 eng d | ||
| 022 | _a1365-2133 | ||
| 024 | 7 |
_a10.1111/j.1365-2133.2008.08891.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPerlmutter, A | |
| 245 | 0 | 0 |
_aTuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. _h[electronic resource] |
| 260 |
_bThe British journal of dermatology _cJan 2009 |
||
| 300 |
_a8-15 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Psoriatic _xdrug therapy |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTuberculosis _xchemically induced |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aMittal, A | |
| 700 | 1 | _aMenter, A | |
| 773 | 0 |
_tThe British journal of dermatology _gvol. 160 _gno. 1 _gp. 8-15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2133.2008.08891.x _zAvailable from publisher's website |
| 999 |
_c18473606 _d18473606 |
||